Core Insights - The stock of Huaren Health experienced a decline of 0.87% on July 31, with a trading volume of 313 million yuan [1] - The company reported a financing buy-in amount of 22.32 million yuan and a net financing buy of 698,200 yuan on the same day [1] - As of July 31, the total financing and securities lending balance for Huaren Health was 139 million yuan, representing 6.26% of its market capitalization [1] Financing and Securities Lending - On July 31, Huaren Health had a financing buy-in of 22.32 million yuan, with a current financing balance of 139 million yuan, which is above the 90th percentile of the past year [1] - The securities lending data showed that on July 31, there were no shares sold short, and the securities lending balance was also zero, indicating a low level of short selling activity [1] Company Overview - Huaren Health, established on June 29, 2001, is located in Hefei, Anhui Province, and was listed on March 1, 2023 [1] - The company's main business segments include pharmaceutical agency, retail, and terminal procurement, with the revenue composition being 80.25% from Western and Chinese medicines, 4.62% from health products, and 4.00% from medical devices [1] Financial Performance - For the period from January to March 2025, Huaren Health achieved a revenue of 1.267 billion yuan, reflecting a year-on-year growth of 14.71% [2] - The net profit attributable to the parent company for the same period was 61.22 million yuan, representing a year-on-year increase of 28.15% [2] Shareholder Information - As of March 31, 2025, the number of shareholders for Huaren Health increased by 9.39% to 18,000, while the average circulating shares per person decreased by 8.58% to 8,309 shares [2] - The company has distributed a total of 80.02 million yuan in dividends since its A-share listing [3] - Notably, Hong Kong Central Clearing Limited has exited the list of the top ten circulating shareholders as of March 31, 2025 [3]